Key Takeaways
- • Jefferies analyst Jonathan Petersen raised Welltower's price target to $248 from $237, a 4.64% increase, while maintaining a Buy rating on the real estate investment trust.
- • The upgrade reflects broad analyst momentum, with BMO Capital simultaneously raising its target to $245 and Citigroup's high estimate reaching $255 as of May 5, 2026.
- • The consensus price target across 27 analysts stands at $176.96, with a range spanning from $183 to $255, indicating meaningful upside potential to Jefferies' revised target.
- • Analyst sentiment remains overwhelmingly positive, with 67% of 12 analyzed firms recommending Buy, 17% Strong Buy, and 17% Hold, with no Sell or Strong Sell ratings.
Summary
Jefferies raised its price target on Welltower Inc. (WELL) to $248 from $237, representing a 4.64% increase while maintaining its Buy rating on the healthcare-focused real estate investment trust. Analyst Jonathan Petersen led the revision, signaling continued confidence in the company's investment thesis and operational trajectory.
The upgrade is part of a broader wave of analyst optimism surrounding Welltower. BMO Capital concurrently raised its price target to $245 from $240, reinforcing institutional conviction in the stock's near-term appreciation potential. Citigroup's May 5, 2026 high estimate of $255 further underscores the bullish consensus forming around the company. These coordinated upgrades from major investment banks suggest strengthening fundamentals or improved visibility into future performance.
Broader analyst consensus supports this upward momentum. Among 27 analysts covering Welltower, the consensus price target stands at $176.96, though this figure reflects the full distribution of opinions. The analyst consensus calls for a 12-month price forecast of $229.67 on average, with estimates ranging from a low of $183 to Citigroup's high of $255. Sentiment metrics are decidedly positive: 67% of the 12 firms analyzed recommend Buy, 17% recommend Strong Buy, and 17% suggest Hold, with no sell-side recommendations recorded.
The coordinated nature of recent upgrades—particularly from Jefferies and BMO Capital—suggests market participants are responding to consistent positive catalysts or improving valuation metrics within the healthcare real estate sector. For institutional investors evaluating healthcare REIT exposure, the alignment of major analyst targets in the $245–$248 range, above the broader consensus mean, may indicate near-term upside relative to current valuations.
The upgrade is part of a broader wave of analyst optimism surrounding Welltower. BMO Capital concurrently raised its price target to $245 from $240, reinforcing institutional conviction in the stock's near-term appreciation potential. Citigroup's May 5, 2026 high estimate of $255 further underscores the bullish consensus forming around the company. These coordinated upgrades from major investment banks suggest strengthening fundamentals or improved visibility into future performance.
Broader analyst consensus supports this upward momentum. Among 27 analysts covering Welltower, the consensus price target stands at $176.96, though this figure reflects the full distribution of opinions. The analyst consensus calls for a 12-month price forecast of $229.67 on average, with estimates ranging from a low of $183 to Citigroup's high of $255. Sentiment metrics are decidedly positive: 67% of the 12 firms analyzed recommend Buy, 17% recommend Strong Buy, and 17% suggest Hold, with no sell-side recommendations recorded.
The coordinated nature of recent upgrades—particularly from Jefferies and BMO Capital—suggests market participants are responding to consistent positive catalysts or improving valuation metrics within the healthcare real estate sector. For institutional investors evaluating healthcare REIT exposure, the alignment of major analyst targets in the $245–$248 range, above the broader consensus mean, may indicate near-term upside relative to current valuations.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.